Samsung Biologics is a fully integrated CDMO with qualified and highly innovative contract development, contract manufacturing, and biosafety testing services.
Latest News
- Samsung Biologics inks $77M with U.S. pharmaceutical - MSN
- Samsung Invests in Generate Biomedicines to Boost AI-Driven Drug Development - BusinessKorea
- Korea's Samsung invests in Generate Biomedicines to advance AI-driven protein therapeutics discovery - BSA bureau
- Samsung Invests in U.S. Biotech Startup to Accelerate AI-Driven Drug Development - The Korea Bizwire
- Samsung Biologics inks $77M deal with U.S. pharmaceutical - The Korea JoongAng Daily
- Samsung Life Science Fund Invests in U.S. Biotech ‘Generate Biomedicines’ - 코메디닷컴
- Samsung invests in US AI biotech firm via Life Science Fund - KBR
- Samsung invests in Generate Biomedicine to enhance AI-driven drug development - 조선비즈 - 조선비즈
- Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery - 한국사회복지저널
- Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery - PR Newswire
- Samsung Biologics signs 111.2 billion won CMO contract with U.S. firm - 조선비즈 - 조선비즈
- Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index - PR Newswire
- Samsung BioLogics earns spot on Dow Jones Sustainability Index for fourth year - 조선비즈 - 조선비즈
- Samsung executives gather for first strategy meeting following impeachment - The Korea JoongAng Daily
- Samsung Life Science Fund reviews new investment options: Sources - 매일경제
